**BIOGA & ALIRA HEALTH: SUPPORT PROGRAM FOR SMEs IN MARKET ACCESS**

**Introduction –** Alira Health ([www.alirahealth.com](http://www.alirahealth.com/)) is an experienced global consulting firm whose mission is to enable healthcare transformation through a wide range of services across the product lifecycle. These services include product development, regulatory, clinical, market access, management consulting, real-world evidence, transaction advisory, advanced analytics, and patient engagement. Alira’s Global Market Access team have recently entered into a collaboration with Organization X and this program is part of this collaboration.

|  |
| --- |
| **PROGRAM OVERVIEW** |
| The program offers support from an experienced team of Market Access consultants to guide companies in enhancing their value proposition, navigating the P&R ecosystem and in appropriately defining their market access needs and ambitions. The program includes a 40-hour package of service including an initial meeting, background analysis, guidance session for funding requests, application reviews andadditional consultations. The program is open for 3 SME’s and participants are selected through acompetitive process. |

|  |
| --- |
| **PROGRAM BASIC INFORMATION** |
| **When** | 2024/2025 | **Language** | English/ Spanish |
| **Duration** | 4 weeks/ Company | **Application** | September-October 2024 |
| **Time Schedule** | 2h/ week (day TBD1) | **Price** | Free of charge |

*1Alira will dedicate a package of 40 hours to support the Company. This package includes hours of weekly meetings and working sessions on a date agreed.*

|  |
| --- |
| **ELIGIBILITY CRITERIA** |
| This support program is eligible for **companies that are**:* MedTech, pharma or biotech Small-Medium Enterprises (SMEs)
* Members of Bioga and Iberobio (the life sciences and healthcare innovation ecosystem in Galicia, Castilla y León, Extremadura, Andalucía and Portugal, meaning the group of companies, research groups and bodies, hospitals, universities, administrations, researchers and entrepreneurs, innovation and knowledgetransfer support structures working in Galicia, Castilla y León, Extremadura, Andalucía and Portugal in this strategic sector)
* Willing to pursue reimbursement/financing for a medical device, IVDR, digital solution or a drug
* Currently seeking funding for market access activities
 |

|  |
| --- |
| **SELECTION PROCESS** |
| A board of GMA directors within Alira Health will select the companies based on:* Calendar and dates of the funding sources according to each applicant interests
* Innovation
* Positive economic impact in the healthcare system
* Impact in the impatient/outpatient management
* Territorial scope

If the number of applicants meeting the selection criteria is higher than 3, a **5-minute pitch** might be necessary as part of the application process |

|  |
| --- |
| **APPLICATION FORM** |
| **Company** | **Applicant** |
| **Name:** | **Name:** |
| **CIF:** | **Position:** |
| **Country (HQ):** | **Email:** |
| **Founded (year):** | **Number:** |
| **Address:** |  |
| **Number of employees:** |  |
| **How would you classify your company?** |
| o **Medtech** | o **IVDR** | o **Digital** |
| o **Pharma** | o **BioTech** | o **Other:** |
| **Product in scope for this project** |
| **Name:** |
| **Description:** |
| **Value proposition:** |
| **Has your product received marketing authorization?** |
| o **Yes, from the EMA** | o **Yes, from FDA** |
| o **Yes, I have CE mark** | o **Yes, from other agencies** |
| o **Not yet** |
| **Current funding** |
| o **<50 K** | o **50 -100 K** | o **100 -250 K** | o **250 -500 K** | o **0.5 – 1M** | o **>1M** |
| **Comment (optional):** |
| **Target funding** |
| **Funding sources of interest:** |
| **Available dates of application:** *(more than one option can be selected)* |
| o **Mar. 2024** | o **Apr. 2024** | o **May. 2024** | o **Jun. 2024** |
| o **Jul. 2024** | o **Aug. 2024** | o **Sep. 2024** | o **Oct. 2024** |
| **Primary Target countries for reimbursement/financing:** |

|  |  |  |
| --- | --- | --- |
| o **National (Spain)** | o **EU41 + UK** | o **Other** |
| **Additional remarks** |
|  |

1Germany, France, Italy and Spain